ClinicalTrials.gg
RecruitingNCT07711626Updated Jul 24, 2026

Foot Reflexology and Ta-VNS for Symptom Management in Head and Neck Cancer During CCRT

An interventional study of True Foot Reflexology and Sham Foot Reflexology in Head and Neck Neoplasms, Xerostomia and Cancer-related Fatigue, sponsored by Tzu Chi University. Recruiting at 1 site in Taiwan. Open to participants aged 30 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-07-24.

Sponsored by Tzu Chi University · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
30 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 118 studies in Head and Neck Neoplasms with a site in Taiwan — 24 open to participants now, 40 under way, 8 of them phase 3. Head and Neck Neoplasms · Taiwan.

Planned enrollment
34th of 95
180 · median 110
Started
2026
with 2 others
No phase
28 of 118
12 open now
Primary completion
2028-12
later than 32 of 39 live
Registered
118th of 118
by date

Among the 118 studies in Head and Neck Neoplasms with a site in Taiwan, this one is the 34th largest by planned enrollment of the 95 interventional ones that give a count, is one of 3 that started in 2026, is one of 28 with no phase, reaches primary completion later than 32 of the 39 other live ones, and was the 118th registered.

Head and Neck Neoplasms

2,717 studies on the registry are indexed under Head and Neck Neoplasms; 599 are open to participants now.

Browse Head and Neck Neoplasms studies →

Open to participants now

24 of the 118 studies in Head and Neck Neoplasms with a site in Taiwan are open now. Recruiting first, the newest first:

18 more — sign in →

All 24 open studies →

A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →

Who these studies take

Of the 458 Head and Neck Neoplasms studies recruiting now, 350 (76%) set no upper age limit and 51 (11%) stop at 75 or younger; 22 take children under 18; 27 take healthy volunteers.

This study: 30 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 118 studies in Head and Neck Neoplasms with a site in Taiwan, or all of them as a file.
02

Study summary

Head and neck cancer (HNC) patients undergoing concurrent chemoradiotherapy (CCRT) frequently experience pain, xerostomia, fatigue, sleep disturbance, and other treatment-related toxicities that impair quality of life and treatment adherence, with incomplete relief from current supportive care. This randomized, single-blind, sham-controlled trial evaluates whether foot reflexology (FR), transcutaneous auricular vagus nerve stimulation (ta-VNS), and auricular acupressure (AA) reduce pain, xerostomia, fatigue, sleep disturbance, and treatment-related symptoms in HNC patients receiving cisplatin-based CCRT, compared with usual care. Participants are randomized to a foot reflexology group, an auricular vagus nerve stimulation group (each with true and sham subgroups), or a usual-care control group, and are followed at baseline and weeks 1, 2, and 4.

Read the detailed description

This is a three-arm parallel, repeated-measures randomized controlled trial conducted in the otolaryngology outpatient and inpatient settings of Hualien Tzu Chi Hospital. Eligible patients with pathologically confirmed HNC (clinical stage II-IVA) scheduled to receive a second cycle of cisplatin-based CCRT are stratified by CRT dose (\<66 Gy vs ≥66 Gy) and randomized using a computer-generated sequence with block size 4 or 8, in a 1:1:1 ratio, to the FR group, the ta-VNS group, or the usual-care control group; the FR and ta-VNS groups are further randomized to true or sham subgroups. The foot reflexology intervention is delivered twice weekly for 20 minutes over two weeks and comprises a relaxation phase, a head-neck/gastrointestinal regulation phase, and a circulation/detoxification phase; the sham condition applies light, non-specific touch. The ta-VNS intervention stimulates the left tragus, cymba conchae, and cavum conchae (pulse width 250 µs, 25 Hz, 0.5-5 mA individualized to a tingling sensation, 30 s on/off) twice weekly for 20 minutes over two weeks; the sham condition stimulates the left earlobe at 0.5 mA. Auricular acupressure with magnetic beads is self-administered three times daily. Outcomes are assessed at T0 (baseline), T1 (week 1), T2 (week 2), and T3 (week 4). Data are analyzed with generalized estimating equation (GEE) models.

03

Conditions studied

  • Head and Neck Neoplasms
  • Xerostomia
  • Cancer-related Fatigue
  • Pain

Keywords

  • Foot Reflexology
  • Transcutaneous Auricular Vagus Nerve Stimulation
  • ta-VNS
  • Auricular Acupressure
  • Head and Neck Cancer
  • Concurrent Chemoradiotherapy
  • Xerostomia
  • Cancer-Related Fatigue
  • Pain
  • Sleep Quality
04

Who can participate

Ages eligible
30 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed head and neck cancer, clinical stage II-IVA, age 30-75 years, conscious, able to communicate and comprehend, and able to comply with study procedures
  • Scheduled to receive a second cycle of cisplatin-based concurrent chemoradiotherapy
  • performance status ≤2

Exclusion criteria

Exclusion Criteria:

  • Severe cognitive impairment or psychiatric illness precluding comprehension or cooperation
  • Open wounds or skin lesions of the foot or ear, lower-limb edema, history of deep vein thrombosis, or diabetes with most recent >7.5%
  • Cardiac pacemaker or other implanted electronic device, or other severe cardiovascular disease
  • Severe bone-marrow suppression (WBC \<2,000/µL or \<50,000/µL)
  • Pregnant or breastfeeding women
  • History of epilepsy or seizures
  • Physically frail condition
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
180 participants (estimated)

Study arms

  • Experimental
    Arm A: Foot Reflexology - True (n=36)

    Procedure: True Foot Reflexology

    Procedure: True Foot Reflexology

  • Sham comparator
    Arm B: Foot Reflexology - Sham (n=36)

    Procedure: Sham Foot Reflexology

    Procedure: Sham Foot Reflexology

  • Experimental
    Arm C: ta-VNS - True (n=36)

    Device: True ta-VNS + Procedure: Auricular Acupressure

    Device: True ta-VNS · Procedure: True Auricular Acupressure

  • Sham comparator
    Arm D: ta-VNS - Sham (n=36)

    Device: Sham ta-VNS + Procedure: Sham Auricular Acupressure

    Device: Sham ta-VNS · Procedure: Sham Auricular Acupressure

  • Active comparator
    Arm E: Usual Care (n=36)

    Other: Usual Care

    Other: Usual Care

Interventions

  • ProcedureTrue Foot Reflexology

    Twice weekly, 20 min, over 2 weeks. Three phases: relaxation (diaphragm, brain, spine zones, 3 min); head-neck function and gastrointestinal regulation (upper/lower GI, thyroid, adrenal zones, 10 min); circulation/detoxification (kidney, lymphatic zones, 7 min).

  • ProcedureSham Foot Reflexology

    Light touch on non-specific foot areas without

  • DeviceTrue ta-VNS

    Left tragus, cymba conchae, cavum conchae; 250 µs, 25 Hz, 0.5-5 mA individualized to tingling, 30 s on/off; twice weekly, 20 min, 2 weeks. Device: Hong-Tai mid-frequency electrotherapy stimulator, model HT66B (TFDA license no. 000637), used off-label for auricular vagus nerve stimulation.

  • DeviceSham ta-VNS

    Left earlobe, 0.5 mA, otherwise identical parameters.

  • ProcedureTrue Auricular Acupressure

    Magnetic beads (1-2 mm) at left tragus, cymba conchae, cavum conchae; 3×/day, \~30 s per point; changed every 2-3 days.

  • ProcedureSham Auricular Acupressure

    Beads at left earlobe (non-vagal regions), same frequency/duration.

  • OtherUsual Care

    Standard CCRT nursing care, antiemetic medication, side-effect prevention education, and symptom monitoring; no study intervention.

06

What researchers measure

Primary outcomes

  1. Change in Numeric Rating Scale (NRS) for pain

    0-10 scale; 0 = no pain, 10 = worst pain.

    Time frame: T0 baseline, T1 week 1, T2 week 2, T3 week 4

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Eisbruch A, Kim HM, Terrell JE, Marsh LH, Dawson LA, Ship JA. Xerostomia and its predictors following parotid-sparing irradiation of head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2001 Jul 1;50(3):695-704. doi: 10.1016/s0360-3016(01)01512-7. PubMed 11395238 ↗
  • Chou YH, Yeh ML, Huang TS, Hsu H. Acupoint stimulation improves pain and quality of life in head and neck cancer patients with chemoradiotherapy: A randomized controlled trial. Asia Pac J Oncol Nurs. 2021 Dec 25;9(1):61-68. doi: 10.1016/j.apjon.2021.11.002. eCollection 2022 Jan. PubMed 35528798 ↗
  • Zuo X, Li Y, Rong X, Yang X, Zhu Y, Pan D, Li H, Shen QY, Tang Y. Efficacy of transcutaneous auricular vagus nerve stimulation on radiotherapy-related neuropathic pain in patients with head and neck cancers (RELAX): protocol for a multicentre, randomised, double-blind, sham-controlled trial. BMJ Open. 2023 Sep 20;13(9):e072724. doi: 10.1136/bmjopen-2023-072724. PubMed 37730386 ↗
  • Mirabile A, Airoldi M, Ripamonti C, Bolner A, Murphy B, Russi E, Numico G, Licitra L, Bossi P. Pain management in head and neck cancer patients undergoing chemo-radiotherapy: Clinical practical recommendations. Crit Rev Oncol Hematol. 2016 Mar;99:100-6. doi: 10.1016/j.critrevonc.2015.11.010. Epub 2015 Dec 3. PubMed 26712589 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Dec 2028, 29 months after the start.

Of 440 non-industry interventional studies with no phase under Head and Neck Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 71. This study's planned 29 months is below that.

Counting every sponsor, half of 458 studies reached it within 33 months; a quarter within 18 and three quarters within 70.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 13, 2026
First posted
Jul 17, 2026
StartActual
Jul 13, 2026
Primary completionEst.
Dec 31, 2028
CompletionEst.
Dec 31, 2028
Last update
Jul 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07711626
Lead sponsor
Tzu Chi University
Collaborators
Hualien Tzu Chi General Hospital
Responsible party
Chun Hou Huang (Associate Professor, Tzu Chi University) — Principal investigator
First posted
Jul 17, 2026
Start date
Jul 13, 2026
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Jul 24, 2026

Study contacts

Yu-Fu Chou MD
Contact
yufuchou@yahoo.com.tw
886-3-8561825
Chun-Hou Huang
Contact
hou2017@gms.tcu.edu.tw

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion